Key result
TAVR yields similar long-term composite outcomes compared to SAVR across trials.
Why the study?
With increasing TAVR utilization in young and low-risk patients with severe aortic stenosis, understanding long-term outcomes of TAVR is critical.
Does TAVR improve long-term outcomes compared to SAVR in patients with severe aortic stenosis?
Does TAVR improve long-term outcomes compared to SAVR in patients with severe aortic stenosis?
Long-term data (6-10 years) from three randomized trials show similar primary composite outcomes between TAVR and SAVR in patients with severe aortic stenosis, though reintervention rates may be higher with certain TAVR platforms.
Answers are grounded in this paper and cite their sources.
Long-term RCT data now available for low-risk AS patients; extends durability evidence for TAVR beyond 5 years.
Transcatheter aortic valve replacement (TAVR) is a more prevalent procedure than surgical aortic valve replacement (SAVR) for severe aortic stenosis (AS). With increasing TAVR utilization in young and low-risk patients, understanding long-term outcomes of TAVR is critical. Three randomized TAVR vs SAVR trials in patients with severe AS were identified with outcomes reported beyond 5 years: the NOTION (10-year outcomes), PARTNER 3 (7-year outcomes), and Evolut Low-Risk (6 year overall outcomes and 7 year reintervention data) trials. Primary trial outcomes, all of which were composite outcomes including all-cause mortality, stroke, myocardial infarction, and/or valve-, procedure-, or heart failure-related readmission, demonstrated similar outcomes between TAVR and SAVR (NOTION: 65.5% vs 65.5%, P=0.9; PARTNER 3: 34.6% vs 37.2%, HR 0.87 [95% CI 0.70-1.08]; Evolut Low Risk: 23.3% vs 20.4%, P=0.43). Amongst secondary outcomes, the cumulative incidence of TAVR reintervention was similar to SAVR reintervention in the NOTION trial (4.3% vs 2.2%, P=0.3) and the PARTNER 3 trial (6.7% vs 6.0%, HR 1.11 [0.63-1.94]), but TAVR reintervention was higher than SAVR reintervention in the Evolut Low-Risk trial (9.8% vs 6.0%; p=0.02). Study limitations include small cohort size (145 undergoing TAVR) of older patients undergoing TAVR with early generation self-expanding TAVRs in the NOTION trial and no data yet beyond 7 years in the PARTNER 3 and Evolut Low-Risk trials. Despite limitations, these data highlight the criticality in extremely careful patient selection for TAVR to optimize long term outcomes in the era of lifetime management of AS.
No takes yet. Share an insight, caveat, or question.
Braasch et al. (2026) conducted a review in Severe aortic stenosis (AS). Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on Composite including all-cause mortality, stroke, myocardial infarction, and/or valve-, procedure-, or heart failure-related readmission. Transcatheter aortic valve replacement demonstrated similar long-term composite outcomes compared to SAVR across three trials.
Synapse has enriched 10 related papers. Consider them for comparative context: